Showing 4951-4960 of 5910 results for "".
- Moderna Hits 30,000 Enrollment Target in Phase 3 Coronavirus Vaccine Trialhttps://modernod.com/news/moderna-hits-30000-enrollment-target-in-phase-3-coronavirus-vaccine-trial/2478450/Moderna announced that it has completed enrollment of 30,000 participants in the phase 3 COVE study of its investigational coronavirus vaccine mRNA-1273. More than 25,650 participants have so far received their second dose, and Moderna said it will decide whether to seek emergency-use autho
- Gilead’s Veklury Becomes First Treatment to Receive FDA Approval for COVID-19https://modernod.com/news/gileads-veklury-becomes-first-treatment-to-receive-fda-approval-for-covid-19/2478451/Gilead Sciences said Thursday that Veklury (remdesivir) has been approved by the FDA to treat hospitalized COVID-19 patients aged 12 years and older and weighing at least 40 kg, making it the first drug to gain full clearance in the US for the disease. The antiviral, which works by hindering the
- Rayner Launches Raytrace Premium IOL Calculator Update to Include Posterior Corneal Astigmatismhttps://modernod.com/news/rayner-launches-raytrace-premium-iol-calculator-update-to-include-posterior-corneal-astigmatism/2478444/Rayner announced the launch of their updated web-based premium IOL calculator, Raytrace. Developed in line with surgeon feedback, the new Raytrace version 3.5 includes the following improvements: Inclusion of Posterior Corneal Astigmatism (PCA) for more accurate toric IOL calculation
- Study Reveals Significant Restoration of Retinal and Visual Function Following Gene Therapyhttps://modernod.com/news/study-reveals-significant-restoration-of-retinal-and-visual-function-following-gene-therapy/2478443/A breakthrough study, led by researchers from the University of California, Irvine, showed significant restoration of retinal and visual function following gene therapy in mice models suffering from inherited retinal disease. Published in Nature Biomedical Engineering, the paper,
- Nevakar Enters into Licensing Agreement in China for NVK-002 for the Treatment of Myopia in Childrenhttps://modernod.com/news/nevakar-enters-into-licensing-agreement-in-china-for-nvk-002-for-the-treatment-of-myopia-in-children/2478434/Nevakar and Hong Kong-based Zhaoke Ophthalmology Pharmaceutical (ZKO) announced have entered into an exclusive licensing agreement for the development and commercialization of Nevakar’s NVK-002 in Greater China, Hong Kong SAR, Macau SAR and Taiwan, South Korea and the Southeast Asian territories.
- Katena Products Acquires Micro-Select Instrumentshttps://modernod.com/news/katena-products-acquires-micro-select-instruments/2478435/Katena Products announced the purchase of Micro-Select Instruments, a maker of ophthalmic instruments including forceps, needle holders, and speculums. Terms of the deal were not disclosed. “The acquisition of Micro-Select is an important addition to Katena’s growing instrument manu
- Innovations Will Propel OCT Market to $549 Million in Revenue in 2020https://modernod.com/news/innovations-will-propel-oct-market-to-549-million-in-revenue-in-202/2478426/Recent innovations in optical coherence tomography (OCT) technology—such as systems that are combined with fundus imagers—and software advancements, including OCT angiography, are growing in popularity. At the same time promising new technologies on the horizon, such as at-home OCT devices, are g
- Blue Light Glasses Improve Sleep and Work Productivity, IU Research Showshttps://modernod.com/news/blue-light-glasses-improve-sleep-and-work-productivity-iu-research-shows/2478421/During the pandemic, the amount of screen time for many people working and learning from home as well as binge-watching TV has sharply increased. New research finds that wearing blue light glasses
- New World Medical Registers New KDB GLIDE for Smooth, Precise Goniotomyhttps://modernod.com/news/new-world-medical-registers-new-kdb-glide-for-smooth-precise-goniotomy/2478414/New World Medical announced FDA registration of the KDB GLIDE as a Class 1 device, designed to give surgeons a refined, precise experience performing excisional goniotomy for treatment of glaucoma. The KDB GLIDE device improves on the successful Kahook Dual Blade technology by adding new features
- Outlook Therapeutics Announces Initiation of Open-Label Safety Study of Lytenava for Wet AMDhttps://modernod.com/news/outlook-therapeutics-announces-initiation-of-open-label-safety-study-for-lytenava-for-wet-amd/2478410/Outlook Therapeutics announced the initiation and enrollment of the first patients in its planned supplemental open-label safety study evaluating ONS-5010/Lytenava (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD) (NORSE THREE). The open-label safety study